Skip to content

Study · Observational study · n = 13 · 2024

6 results

Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.

Vanek L, Kurnikowski A, Krenn S, Mussnig S, Hecking M

Diabetes, obesity & metabolism7 Oct 2024Cited by 21 (Europe PMC)

PMID39375862 (opens in a new tab)DOI10.1111/dom.15967 (opens in a new tab)PepBankPUB-39375862
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity on dialysis, 12 weeks of semaglutide reduced body weight by an average of 4.6 kg.

    In plain wordsIn adults with obesity on dialysis, 12 weeks of semaglutide lowered body weight by an average of 4.6 kg.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at week 12
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg, then 0.5 mg, then 1 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Mean weight reduction
    4.6 kg
    week 12

    Source sentences

    Summary
    At week 12, average weight reduction under semaglutide treatment was 4.6 ± 2.4 kg and ranged from 2.0 to 9.7 kg (p < 0.001 for weight and BMI reduction across the study period).
    2 context sentences
    Summary · context
    Study endpoints included change in body weight and BMI (primary - statistically evaluated by repeated measures analysis of variance [ANOVA]), side effects, adverse events, blood parameters and patient-reported outcomes (secondary).
    Summary · context
    We conducted a prospective 12-week, open-label trial with 13 patients who had a BMI ≥ 30.00 kg/m2, were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity on dialysis, BMI fell significantly over 12 weeks of semaglutide treatment.

    In plain wordsIn adults with obesity on dialysis, 12 weeks of semaglutide lowered BMI.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change over 12 weeks
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg, then 0.5 mg, then 1 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 12, average weight reduction under semaglutide treatment was 4.6 ± 2.4 kg and ranged from 2.0 to 9.7 kg (p < 0.001 for weight and BMI reduction across the study period).
    1 context sentence
    Summary · context
    We conducted a prospective 12-week, open-label trial with 13 patients who had a BMI ≥ 30.00 kg/m2, were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight.
  3. 03HumanObservational studySafety outcome

    In adults with obesity on dialysis, one of 13 patients stopped semaglutide because of nausea or vomiting.

    In plain wordsIn adults with obesity on dialysis, one patient stopped semaglutide because of nausea or vomiting.

    Peptide
    Semaglutide
    Outcome
    Not applicableDiscontinuation due to nausea or vomiting
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg, then 0.5 mg, then 1 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    One patient discontinued treatment due to nausea/vomiting
    1 context sentence
    Summary · context
    We conducted a prospective 12-week, open-label trial with 13 patients who had a BMI ≥ 30.00 kg/m2, were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight.
  4. 04HumanObservational studySafety outcome

    In adults with obesity on dialysis, two patients died of causes that the authors judged unrelated to semaglutide.

    In plain wordsIn adults with obesity on dialysis, two patients died of causes that the authors said were unrelated to semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableDeaths during treatment
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Mortality · Whole body
    Studied dose
    0.25 mg, then 0.5 mg, then 1 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    two patients died of unrelated causes
    1 context sentence
    Summary · context
    We conducted a prospective 12-week, open-label trial with 13 patients who had a BMI ≥ 30.00 kg/m2, were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight.
  5. 05HumanObservational studySafety outcome

    In adults with obesity on dialysis, six of 13 patients reported side effects during semaglutide treatment.

    In plain wordsIn adults with obesity on dialysis, six patients reported side effects while taking semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePatients reporting side effects
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.25 mg, then 0.5 mg, then 1 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    six patients reported side effects.
    1 context sentence
    Summary · context
    We conducted a prospective 12-week, open-label trial with 13 patients who had a BMI ≥ 30.00 kg/m2, were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight.
  6. 06HumanObservational studyEfficacy outcome

    About 9 months after semaglutide started, three of 13 patients with obesity on dialysis could seriously reconsider being listed for transplantation.

    In plain wordsIn adults with obesity on dialysis, three patients could consider joining the transplant list about 9 months after starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePatients able to reconsider transplant listing
    Study

    n = 13

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.25 mg, then 0.5 mg, then 1 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Approximately 9 months after the treatment started, three patients were able to seriously reconsider being listed for transplantation.
    1 context sentence
    Summary · context
    We conducted a prospective 12-week, open-label trial with 13 patients who had a BMI ≥ 30.00 kg/m2, were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.